Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib + Tocilizumab in SR-aGVHD
NCT04070781Phase 1Terminated
- Sponsor
- Columbia University
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of itacitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Columbia University. Primary endpoints: Maximum Tolerated Dose and Safety and Tolerability at 28 days. Started Jan 2020; status: terminated.
02
Drugs
itacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT04070781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04070781.